Skip to main content

Home/ Dr. Goodyear/ Group items tagged CD4:CD8

Rss Feed Group items tagged

Filter: All | Bookmarks | Topics Simple Middle
Nathan Goodyear

Role of IL-2 in cancer immunotherapy: OncoImmunology: Vol 5, No 6 - 1 views

www.tandfonline.com/...2162402X.2016.1163462

IL-2 cancer immune system

shared by Nathan Goodyear on 17 Apr 18 - No Cached
  • IL-2 is one of the key cytokines with pleiotropic effects on the immune system
  • IL-2 as “T-cell growth factor”
  • approved for the treatment of metastatic renal cell carcinoma (1992) and later for metastatic melanoma (1998) by FDA
  • ...13 more annotations...
  • It is produced predominately by antigen-simulated CD4+ T cells, while it can also be produced by CD8+ cells, natural killer (NK) cells, and activated dendritic cells (DC)
  • IL-2 is an important factor for the maintenance of CD4+ regulatory T cells
  • plays a critical role in the differentiation of CD4+ T cells into a variety of subsets
  • It can promote CD8+ T-cell and NK cell cytotoxicity activity, and modulate T-cell differentiation programs in response to antigen, promoting naive CD4+ T-cell differentiation into T helper-1 (Th1) and T helper-2 (Th2) cells while inhibiting T helper-17 (Th17) differentiation
  • Of note, Tregs, which act to dampen the immune response, constitutively express high levels of α chain
  • IL-2Rα is unique to IL-2 and is expressed by a number of immune cells including T regulatory cells (Treg), activated CD4+ and CD8+T cells, B cells, mature DCs, endothelial cells
  • some investigators evaluated the efficacy of regimens containing low-dose IL-2
  • IL-2 can promote the activation and cell growth of T and NK cells
  • Unfortunately, not all of patients would benefit from targeted therapy and nearly all patients who initially respond to targeted inhibitors inevitably develop acquired resistance to the treatment
  • IL-2 also stimulates T-regulatory cells that constitutively express CTLA-4 and can suppress immune reactions. Hence, IL-2 might enhance antitumor reactivity in the presence of CTLA-4 blockade
  • both HD and low-dose IL-2 therapy preferentially induce the expansion of CD4+CD25+Foxp3+ Treg and the Treg level remains elevated after each cycle of HD IL-2 therapy
  • Due to rapid elimination and metabolism via the kidney, IL-2 has a short serum half-life of several minutes
  • HD IL-2-induced severe toxicities including vascular leak syndrome (VLS), pulmonary edema, hypotension, and heart toxicities
  • Nathan Goodyear on 17 Apr 18
     
    Great historical and functional role of IL-2 in the fight against cancer.
Nathan Goodyear

Effector CD4 and CD8 T Cells and Their Role in the Tumor Microenvironment | SpringerLink - 0 views

link.springer.com/...s12307-012-0127-6

cancer CD4 CD8 immune system

shared by Nathan Goodyear on 24 Dec 18 - No Cached
  • Nathan Goodyear on 24 Dec 18
     
    Great review of the CD4 and CD8 cells in the tumor microenvironment and their role in cancer progression or cancer control
Nathan Goodyear

http://www.ijcep.com/files/ijcep0047644.pdf - 0 views

www.ijcep.com/...ijcep0047644.pdf

immune system immunotherapy CD4:CD8 cancer breast cancer

shared by Nathan Goodyear on 09 Nov 18 - No Cached
  • Nathan Goodyear on 09 Nov 18
     
    Increased CD4:CD8 associated with increased progression of cancer.
Nathan Goodyear

The psychoneuroendocrine-immunotherapy of cancer: Historical evolution and clinical res... - 0 views

www.ncbi.nlm.nih.gov/...PMC5426095

cancer melatonin immunotherapy

shared by Nathan Goodyear on 10 May 18 - No Cached
  • It is known that immune system-induced destruction of cancer cells is mainly mediated by T cytotoxic lymphocytes (CD8+) and NK cells (CD16+), respectively, through an antigen-specific and an antigen nonspecific cytotoxicity
  • NK cells are mainly stimulated by IL-2 released by T helper-1 (TH1) lymphocytes (CD4+) while T cytotoxic lymphocytes (CD8+) are namely under a stimulatory control released by IL-12 produced by the dendritic cells
  • On the other hand, the anticancer immunity is inhibited by the activation of the macrophage system through the production of suppressive cytokines, such as IL-6 and T regulatory (T reg) lymphocytes (CD4+CD25+), which counteract the anticancer immunity by producing immunosuppressive cytokines inhibiting the secretion of both IL-2 and IL-12, including TGF-beta and IL-10, or by a direct cell-cell contact
  • Nathan Goodyear on 10 May 18
     
    to be read review of melatonin in cancer treatment.
Nathan Goodyear

Mistletoe and Immunomodulation: Insights and Implications for Anticancer Therapies - 0 views

www.hindawi.com/...5893017

NK cells cancer immune system Th1 immunotherapy mistletoe

shared by Nathan Goodyear on 16 Oct 20 - No Cached
  • Nathan Goodyear on 16 Oct 20
     
    Mistletoe increases CD4:CD8 due to increase in Th1 but decrease in Treg; also increase in NK cells. Very important immunomodulatory effect.
Nathan Goodyear

A novel mechanism of lung cancer inhibition by methionine enkephalin through remodeling... - 0 views

www.researchgate.net/..._of_the_tumor_microenvironment

M2 macrophages M1 macrophages cancer MET-enkephalins TME MET-5 tumor microenvironment

shared by Nathan Goodyear on 15 Aug 21 - No Cached
  • Nathan Goodyear on 15 Aug 21
     
    MENK increased the infiltration of M1-type macrophages, natural killer cells, CD8+ T cells, CD4+ T cells, and dendritic cells into the TME, and decreased the proportion of myeloid inhibitory cells and M2-type macrophages. Plays particular role in preventing immune escape and immune dysfunction paramount to cancer metastasis
Nathan Goodyear

IL-2: The First Effective Immunotherapy for Human Cancer | The Journal of Immunology - 0 views

www.jimmunol.org/...5451

cancer IL-2 Treg immune system immunology

shared by Nathan Goodyear on 17 Apr 18 - No Cached
  • IL-2 is a 15.5-kDa cytokine secreted predominately by Ag-simulated CD4+ T cells, but it can also be produced by CD8+ cells, NK cells, and activated dendritic cells
  • IL-2 is the predominant factor responsible for the maintenance of CD4+ regulatory T cells
  • A generalized capillary leak syndrome was induced by IL-2 in vivo that resulted in interstitial pulmonary infiltrates and substantial weight gain in patients
  • ...4 more annotations...
  • The side effects were transient and returned to baseline following treatment
  • Tumors do not express IL-2 receptors and thus the antitumor activity was the result of IL-2 stimulation of immune cell
  • Patients with metastatic melanoma or metastatic renal cell cancer were uniquely responsive to high-dose IL-2 administration, and except for patients with advanced non-Hodgkin’s lymphomas (35) only rare responses were seen in patients with other tumor types
  • The underlying toxicity of IL-2 results from a capillary leak that leads to fluid extravasation into visceral organs that can compromise their function
  • Nathan Goodyear on 17 Apr 18
     
    Great review of the history of IL-2 in the treatment of cancer.  IL-2 stimulates the immune system to attack cancer.  Don't reinvent the wheel; use what is already present and available.
Nathan Goodyear

T-cell subsets (Th1 versus Th2). - PubMed - NCBI - 0 views

www.ncbi.nlm.nih.gov/...10923599

interleukins Th1 Th2 immune system autoimmune disease CD4 CD8

shared by Nathan Goodyear on 11 Jan 17 - No Cached
  • Nathan Goodyear on 11 Jan 17
     
    only abstract available: Review of the cell mediated immune system and the interleukin signaling.
Nathan Goodyear

Role of certain trace minerals in oxidative stress, inflammation, CD4/CD8 lymphocyte ra... - 0 views

acb.sagepub.com/...344.abstract

asthma selenium zinc copper glutathione hs-CRP TBARS FEV1 FVC catalase inflammation minerals

shared by Nathan Goodyear on 07 Jul 16 - No Cached
  • Nathan Goodyear on 07 Jul 16
     
    Asthma associated with low selenium, low zinc, high copper, low glutathione peroxidase, glutathione reductase, and catalase activity; in contrast, increased hs-CRP, and TBARS was  noted.  Interesting that FEV1 and FVC positively correlated with Se levels.
Nathan Goodyear

Update on Programmed Death-1 and Programmed Death-Ligand 1 Inhibition in the Treatment ... - 0 views

www.ncbi.nlm.nih.gov/...PMC5382272

cancer PD-1 immunotherapy programmed death-1

shared by Nathan Goodyear on 20 Apr 18 - No Cached
  • Cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), the first immune checkpoint receptor to be clinically targeted, is exclusively expressed on the surface of CD4+ and CD8+ T cells in lymphatic tissue and is involved in T-cell regulation, proliferation, and tolerance
  • programmed death-1 (PD-1) immune checkpoint inhibitor antibodies, which restores T-cell effector function and augments the host anti-tumor response by blocking the binding of either programmed death-ligand 1 (PD-L1) and/or PD-L2 to PD-1 receptors
  • lung cancer is the first and second cause of cancer mortality in men and women
  • ...1 more annotation...
  • Eighty-five percent of lung cancers are non-small-cell lung cancer (NSCLC)
  • Nathan Goodyear on 20 Apr 18
     
    To read update article on PD-1 and immunotherapy.
1 - 11 of 11
Showing 20▼ items per page